Healthcare solutions provider Molbio Diagnostics raised $85 million in funds from Temasek

September 26, 2022

, By Team SNFYI

Share via:

Healthcare solutions provider Molbio Diagnostics raised $85 million in funds from Singapore-based investment firm Temasek.

Molbio Diagnostics is well-known for its ‘Truenat’ technology, which is a portable, battery-powered real-time PCR platform for testing infectious diseases such as tuberculosis, COVID-19, Hepatitis-C virus, human papillomavirus, influenza, and vector-borne diseases such as dengue, chikungunya, and malaria. Temasek’s new funds, along with those from existing investors like Motilal Oswal Alternates, will assist the company in accelerating the development and commercialization of new technologies based on clinical need gaps. This will also aid the company’s efforts to bring the Truenat platform to global markets.

Disclaimer

We strive to uphold the highest ethical standards in all of our reporting and coverage. We StartupNews.fyi want to be transparent with our readers about any potential conflicts of interest that may arise in our work. It’s possible that some of the investors we feature may have connections to other businesses, including competitors or companies we write about. However, we want to assure our readers that this will not have any impact on the integrity or impartiality of our reporting. We are committed to delivering accurate, unbiased news and information to our audience, and we will continue to uphold our ethics and principles in all of our work. Thank you for your trust and support.

Previous News

Centre issued blocking orders for several “Innocuous” Tweets

Next News

Mahindra Logistics Ltd. acquires B2B express business of Rivigo Services for ₹225 crore

Popular

More Like this

Healthcare solutions provider Molbio Diagnostics raised $85 million in funds from Temasek

September 26, 2022

, By Team SNFYI

Healthcare solutions provider Molbio Diagnostics raised $85 million in funds from Singapore-based investment firm Temasek.

Molbio Diagnostics is well-known for its ‘Truenat’ technology, which is a portable, battery-powered real-time PCR platform for testing infectious diseases such as tuberculosis, COVID-19, Hepatitis-C virus, human papillomavirus, influenza, and vector-borne diseases such as dengue, chikungunya, and malaria. Temasek’s new funds, along with those from existing investors like Motilal Oswal Alternates, will assist the company in accelerating the development and commercialization of new technologies based on clinical need gaps. This will also aid the company’s efforts to bring the Truenat platform to global markets.

Disclaimer

We strive to uphold the highest ethical standards in all of our reporting and coverage. We StartupNews.fyi want to be transparent with our readers about any potential conflicts of interest that may arise in our work. It’s possible that some of the investors we feature may have connections to other businesses, including competitors or companies we write about. However, we want to assure our readers that this will not have any impact on the integrity or impartiality of our reporting. We are committed to delivering accurate, unbiased news and information to our audience, and we will continue to uphold our ethics and principles in all of our work. Thank you for your trust and support.

Website Upgradation is going on for any glitch kindly connect at office@startupnews.fyi

Previous News

Centre issued blocking orders for several “Innocuous” Tweets

Next News

Mahindra Logistics Ltd. acquires B2B express business of Rivigo Services for ₹225 crore

More like this

Popular

Upcoming Events

Startup Information that matters. Get in your inbox Daily!